FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ENPP1-RIPPLY2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ENPP1-RIPPLY2
FusionPDB ID: 26647
FusionGDB2.0 ID: 26647
HgeneTgene
Gene symbol

ENPP1

RIPPLY2

Gene ID

5167

134701

Gene nameectonucleotide pyrophosphatase/phosphodiesterase 1ripply transcriptional repressor 2
SynonymsARHR2|COLED|M6S1|NPP1|NPPS|PC-1|PCA1|PDNP1C6orf159|SCDO6|dJ237I15.1
Cytomap

6q23.2

6q14.2

Type of geneprotein-codingprotein-coding
Descriptionectonucleotide pyrophosphatase/phosphodiesterase family member 1E-NPP 1Ly-41 antigenalkaline phosphodiesterase 1membrane component, chromosome 6, surface marker 1phosphodiesterase I/nucleotide pyrophosphatase 1plasma-cell membrane glycoprotein 1plaprotein ripply2ripply2 homolog
Modification date2020031320200313
UniProtAcc

P22413

Main function of 5'-partner protein: FUNCTION: Nucleotide pyrophosphatase that generates diphosphate (PPi) and functions in bone mineralization and soft tissue calcification by regulating pyrophosphate levels (By similarity). PPi inhibits bone mineralization and soft tissue calcification by binding to nascent hydroxyapatite crystals, thereby preventing further growth of these crystals (PubMed:11004006). Preferentially hydrolyzes ATP, but can also hydrolyze other nucleoside 5' triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3',5'-cAMP to AMP (PubMed:27467858, PubMed:8001561, PubMed:25344812). May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling (PubMed:27467858, PubMed:8001561). Inhibits ectopic joint calcification and maintains articular chondrocytes by repressing hedgehog signaling; it is however unclear whether hedgehog inhibition is direct or indirect (By similarity). Appears to modulate insulin sensitivity and function (PubMed:10615944). Also involved in melanogenesis (PubMed:28964717). Also able to hydrolyze 2'-3'-cGAMP (cyclic GMP-AMP), a second messenger that activates TMEM173/STING and triggers type-I interferon production (PubMed:25344812). 2'-3'-cGAMP degradation takes place in the lumen or extracellular space, and not in the cytosol where it is produced; the role of 2'-3'-cGAMP hydrolysis is therefore unclear (PubMed:25344812). Not able to hydrolyze the 2'-3'-cGAMP linkage isomer 3'-3'-cGAMP (PubMed:25344812). {ECO:0000250|UniProtKB:P06802, ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:25344812, ECO:0000269|PubMed:27467858, ECO:0000269|PubMed:28964717, ECO:0000269|PubMed:8001561, ECO:0000305|PubMed:11004006}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000360971, ENST00000369687, 
ENST00000369689, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 6 X 4=1442 X 2 X 2=8
# samples 62
** MAII scorelog2(6/144*10)=-1.26303440583379
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(2/8*10)=1.32192809488736
Fusion gene context

PubMed: ENPP1 [Title/Abstract] AND RIPPLY2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ENPP1 [Title/Abstract] AND RIPPLY2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ENPP1(132129415)-RIPPLY2(84563816), # samples:2
Anticipated loss of major functional domain due to fusion event.ENPP1-RIPPLY2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ENPP1-RIPPLY2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ENPP1-RIPPLY2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ENPP1-RIPPLY2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneENPP1

GO:0006091

generation of precursor metabolites and energy

12746903

HgeneENPP1

GO:0006796

phosphate-containing compound metabolic process

10513816|11159191

HgeneENPP1

GO:0009143

nucleoside triphosphate catabolic process

10513816

HgeneENPP1

GO:0030308

negative regulation of cell growth

17849011

HgeneENPP1

GO:0030505

inorganic diphosphate transport

10513816

HgeneENPP1

GO:0030643

cellular phosphate ion homeostasis

11159191

HgeneENPP1

GO:0030730

sequestering of triglyceride

17849011

HgeneENPP1

GO:0031953

negative regulation of protein autophosphorylation

11289049

HgeneENPP1

GO:0032869

cellular response to insulin stimulus

7830796|17849011

HgeneENPP1

GO:0045599

negative regulation of fat cell differentiation

17849011

HgeneENPP1

GO:0045719

negative regulation of glycogen biosynthetic process

11289049

HgeneENPP1

GO:0046325

negative regulation of glucose import

17849011

HgeneENPP1

GO:0046627

negative regulation of insulin receptor signaling pathway

7830796|17849011

HgeneENPP1

GO:0050427

3'-phosphoadenosine 5'-phosphosulfate metabolic process

7830796

HgeneENPP1

GO:0090305

nucleic acid phosphodiester bond hydrolysis

22285541



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:132129415/chr6:84563816)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ENPP1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RIPPLY2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000360971ENPP1chr6132129415+ENST00000369689RIPPLY2chr684563816+59926020472150
ENST00000360971ENPP1chr6132129415+ENST00000369687RIPPLY2chr684563816+59926020472150

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000360971ENST00000369689ENPP1chr6132129415+RIPPLY2chr684563816+0.0084230760.9915769
ENST00000360971ENST00000369687ENPP1chr6132129415+RIPPLY2chr684563816+0.0084230760.9915769

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ENPP1-RIPPLY2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ENPP1chr6132129415RIPPLY2chr68456381626075AARARTAKDPNTYKVLSLMPDGPGMT

Top

Potential FusionNeoAntigen Information of ENPP1-RIPPLY2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ENPP1-RIPPLY2_132129415_84563816.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B52:01NTYKVLSL0.9870.62461018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A30:08TAKDPNTYK0.99480.6768514
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B15:17NTYKVLSLM0.99110.76641019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:01AKDPNTYKV0.8810.8679615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:13AKDPNTYKV0.86890.8852615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B38:01AKDPNTYKV0.85250.9269615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B38:02AKDPNTYKV0.84980.9347615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A30:08RTAKDPNTYK0.99880.6761414
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:13AKDPNTYKVL0.88930.844616
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A30:08ARTAKDPNTYK0.99340.7356314
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C15:06NTYKVLSL0.99970.86811018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C03:19NTYKVLSL0.99970.97261018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C03:08NTYKVLSL0.99960.87351018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C12:04NTYKVLSL0.99650.99111018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B51:07NTYKVLSL0.98380.55131018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B14:03NTYKVLSL0.95580.57141018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C15:04NTYKVLSLM0.99770.76631019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C15:06NTYKVLSLM0.99520.81141019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C12:12NTYKVLSLM0.89110.9241019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:09AKDPNTYKV0.86250.5843615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:05AKDPNTYKV0.81780.8507615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C06:03NTYKVLSLM0.76250.98831019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C12:04NTYKVLSLM0.76170.98781019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:08AKDPNTYKV0.54990.8264615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C07:13AKDPNTYKV0.49570.8696615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C04:14AKDPNTYKV0.37480.7722615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C05:09TAKDPNTYKV0.9930.8815515
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C08:15TAKDPNTYKV0.93790.9573515
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:08AKDPNTYKVL0.89450.7022616
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:10DPNTYKVLSL0.59840.6494818
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B27:14ARTAKDPNTYK0.99970.6446314
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C03:17NTYKVLSL0.99980.89351018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C03:05NTYKVLSL0.99970.86281018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C15:02NTYKVLSL0.99970.81451018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C15:05NTYKVLSL0.99970.83791018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C12:03NTYKVLSL0.9990.9761018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C16:01NTYKVLSL0.99690.97481018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C16:02NTYKVLSL0.99550.98021018
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C14:03TYKVLSLM0.95340.95651119
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C14:02TYKVLSLM0.95340.95651119
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C18:01AKDPNTYKV0.99860.7908615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C15:09NTYKVLSLM0.99770.76631019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A30:01TAKDPNTYK0.99340.7571514
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C15:02NTYKVLSLM0.99240.72931019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A25:01NTYKVLSLM0.98270.83361019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A69:01NTYKVLSLM0.93240.5581019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:02AKDPNTYKV0.91930.8892615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C12:03NTYKVLSLM0.90040.97091019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B38:05AKDPNTYKV0.85250.9269615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C06:06AKDPNTYKV0.69660.9815615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:11AKDPNTYKV0.4860.725615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C02:02NTYKVLSLM0.46280.92981019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C02:10NTYKVLSLM0.46280.92981019
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B15:09AKDPNTYKV0.40250.5237615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C07:04AKDPNTYKV0.28490.9418615
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A30:01RTAKDPNTYK0.99890.7842414
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C04:03TAKDPNTYKV0.9930.8044515
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C05:01TAKDPNTYKV0.9930.8815515
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:02AKDPNTYKVL0.96580.8445616
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-C08:02TAKDPNTYKV0.93790.9573515
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B39:11AKDPNTYKVL0.93740.575616
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A69:01TAKDPNTYKV0.71040.7429515
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-B27:10ARTAKDPNTYK0.99960.8149314
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A30:01RTAKDPNTYKV0.99680.9214415
ENPP1-RIPPLY2chr6132129415chr684563816260HLA-A30:01ARTAKDPNTYK0.99490.8494314

Top

Potential FusionNeoAntigen Information of ENPP1-RIPPLY2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ENPP1-RIPPLY2_132129415_84563816.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0405PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0405DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0409PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0417PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0417DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0424PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0424DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0429PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0429DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0430PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0430DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0445PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0445DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0448PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0448DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0454PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0457PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0457DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0477PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0477DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0480PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0480DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0482PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0483PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0483DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0484PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0484DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0486PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0486DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0487PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0487DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0489PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0489DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0801PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0801DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0803PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0803DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0805PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0805DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0807PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0808PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0808DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0811PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0811DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0814PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0814DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0816PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0816DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0818PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0818DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0823PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0823DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0826PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0826DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0827PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0827DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0829PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0829DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0832PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0832DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0832KDPNTYKVLSLMPDG722
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0832NTYKVLSLMPDGPGM1025
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0833PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0833DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0835PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0835DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0836PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0836DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0837PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0837DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0838PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0838DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0839PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0839DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0840PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-0840DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1130PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1216PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1312PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1313PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1321PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1330PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1349PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1355PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1413PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1413DPNTYKVLSLMPDGP823
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1422PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1425PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1463PNTYKVLSLMPDGPG924
ENPP1-RIPPLY2chr6132129415chr684563816260DRB1-1485PNTYKVLSLMPDGPG924

Top

Fusion breakpoint peptide structures of ENPP1-RIPPLY2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
308AKDPNTYKVLSLMPENPP1RIPPLY2chr6132129415chr684563816260

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ENPP1-RIPPLY2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN308AKDPNTYKVLSLMP-7.9962-8.1096
HLA-B14:023BVN308AKDPNTYKVLSLMP-5.70842-6.74372
HLA-B52:013W39308AKDPNTYKVLSLMP-6.83737-6.95077
HLA-B52:013W39308AKDPNTYKVLSLMP-4.4836-5.5189
HLA-A11:014UQ2308AKDPNTYKVLSLMP-10.0067-10.1201
HLA-A11:014UQ2308AKDPNTYKVLSLMP-9.03915-10.0745
HLA-A24:025HGA308AKDPNTYKVLSLMP-6.56204-6.67544
HLA-A24:025HGA308AKDPNTYKVLSLMP-5.42271-6.45801
HLA-B44:053DX8308AKDPNTYKVLSLMP-7.85648-8.89178
HLA-B44:053DX8308AKDPNTYKVLSLMP-5.3978-5.5112
HLA-A02:016TDR308AKDPNTYKVLSLMP-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ENPP1-RIPPLY2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ENPP1-RIPPLY2chr6132129415chr6845638161018NTYKVLSLCTCTCGCTGATGCCCGATGGCCCT
ENPP1-RIPPLY2chr6132129415chr6845638161019NTYKVLSLMCTCTCGCTGATGCCCGATGGCCCTGGA
ENPP1-RIPPLY2chr6132129415chr6845638161119TYKVLSLMTCGCTGATGCCCGATGGCCCTGGA
ENPP1-RIPPLY2chr6132129415chr684563816314ARTAKDPNTYKGACCCCAACACCTATAAAGTACTCTCGCTGATG
ENPP1-RIPPLY2chr6132129415chr684563816414RTAKDPNTYKCCCAACACCTATAAAGTACTCTCGCTGATG
ENPP1-RIPPLY2chr6132129415chr684563816415RTAKDPNTYKVCCCAACACCTATAAAGTACTCTCGCTGATGCCC
ENPP1-RIPPLY2chr6132129415chr684563816514TAKDPNTYKAACACCTATAAAGTACTCTCGCTGATG
ENPP1-RIPPLY2chr6132129415chr684563816515TAKDPNTYKVAACACCTATAAAGTACTCTCGCTGATGCCC
ENPP1-RIPPLY2chr6132129415chr684563816615AKDPNTYKVACCTATAAAGTACTCTCGCTGATGCCC
ENPP1-RIPPLY2chr6132129415chr684563816616AKDPNTYKVLACCTATAAAGTACTCTCGCTGATGCCCGAT
ENPP1-RIPPLY2chr6132129415chr684563816818DPNTYKVLSLAAAGTACTCTCGCTGATGCCCGATGGCCCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ENPP1-RIPPLY2chr6132129415chr6845638161025NTYKVLSLMPDGPGMCTCTCGCTGATGCCCGATGGCCCTGGAATGACCGCAGCCTCAGGA
ENPP1-RIPPLY2chr6132129415chr684563816722KDPNTYKVLSLMPDGTATAAAGTACTCTCGCTGATGCCCGATGGCCCTGGAATGACCGCA
ENPP1-RIPPLY2chr6132129415chr684563816823DPNTYKVLSLMPDGPAAAGTACTCTCGCTGATGCCCGATGGCCCTGGAATGACCGCAGCC
ENPP1-RIPPLY2chr6132129415chr684563816924PNTYKVLSLMPDGPGGTACTCTCGCTGATGCCCGATGGCCCTGGAATGACCGCAGCCTCA

Top

Information of the samples that have these potential fusion neoantigens of ENPP1-RIPPLY2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAENPP1-RIPPLY2chr6132129415ENST00000360971chr684563816ENST00000369687TCGA-OL-A6VO-01A

Top

Potential target of CAR-T therapy development for ENPP1-RIPPLY2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ENPP1-RIPPLY2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ENPP1-RIPPLY2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource